MAP2K7 and liver cancer: For example, it has been mentioned in some studies that PAQR3 can inhibit MEK pathway activity in liver cancer, colorectal cancer and other tumors, and our analysis found that the expression level of PAQR3 is positively correlated with the effect of MEK inhibitors.